title: New insights into tetrahydrobiopterin pharmacodynamics from Pah enu1/2, a mouse model for compound heterozygous tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.
abstract: Phenylketonuria (PKU), an autosomal recessive disease with phenylalanine hydroxylase (PAH) deficiency, was recently shown to be a protein misfolding disease with loss-of-function. It can be treated by oral application of the natural PAH cofactor tetrahydrobiopterin (BH(4)) that acts as a pharmacological chaperone and rescues enzyme function in vivo. Here we identified Pah(enu1/2) bearing a mild and a severe mutation (V106A/F363S) as a new mouse model for compound heterozygous mild PKU. Although BH(4) treatment has become established in clinical routine, there is substantial lack of knowledge with regard to BH(4) pharmacodynamics and the effect of the genotype on the response to treatment with the natural cofactor. To address these questions we applied an elaborate methodological setup analyzing: (i) blood phenylalanine elimination, (ii) blood phenylalanine/tyrosine ratios, and (iii) kinetics of in vivo phenylalanine oxidation using (13)C-phenylalanine breath tests. We compared pharmacodynamics in wild-type, Pah(enu1/1), and Pah(enu1/2) mice and observed crucial differences in terms of effect size as well as effect kinetics and dose response. Results from in vivo experiments were substantiated in vitro after overexpression of wild-type, V106A, and F263S in COS-7 cells. Pharmacokinetics did not differ between Pah(enu1/1) and Pah(enu1/2) indicating that the differences in pharmacodynamics were not induced by divergent pharmacokinetic behavior of BH(4). In conclusion, our findings show a significant impact of the genotype on the response to BH(4) in PAH deficient mice. This may lead to important consequences concerning the diagnostic and therapeutic management of patients with PAH deficiency underscoring the need for individualized procedures addressing pharmacodynamic aspects.
authors: Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, 6020 Innsbruck, Austria.
authors: Florian B
authors: FB
authors: Lagler
authors: Søren W
authors: SW
authors: Gersting
authors: Clemens
authors: C
authors: Zsifkovits
authors: Alice
authors: A
authors: Steinbacher
authors: Anna
authors: A
authors: Eichinger
authors: Marta K
authors: MK
authors: Danecka
authors: Michael
authors: M
authors: Staudigl
authors: Ralph
authors: R
authors: Fingerhut
authors: Hartmut
authors: H
authors: Glossmann
authors: Ania C
authors: AC
authors: Muntau
mesh_terms: D000818:Animals; D001708:Biopterins / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D001944:Breath Tests; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006579:Heterozygote; D051379:Mice; D008817:Mice, Mutant Strains; D009154:Mutation; D010649:Phenylalanine / Q000097:blood; D010651:Phenylalanine Hydroxylase / Q000172:deficiency* / Q000235:genetics; D010661:Phenylketonurias / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D016896:Treatment Outcome; D014443:Tyrosine / Q000097:blood
chemical_list: D001708:Biopterins; D014443:Tyrosine; D010649:Phenylalanine; D010651:Phenylalanine Hydroxylase; C003402:sapropterin